Grifols SA

GRFS

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    23,800

Grifols SA News & Analysis

stocks

6 undervalued stocks with low beta

Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,954.60104.20-1.15%
CAC 408,265.413.250.04%
DAX 4024,635.40144.340.59%
Dow JONES (US)49,709.54800.821.64%
FTSE 10010,354.5145.290.44%
HKSE26,559.95325.29-1.21%
NASDAQ22,722.14181.550.81%
Nikkei 22554,253.68435.640.81%
NZX 50 Index13,444.0223.27-0.17%
S&P 5006,869.7371.331.05%
S&P/ASX 2008,708.8096.70-1.10%
SSE Composite Index4,065.5810.33-0.25%

Market Movers